{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:09:43Z","timestamp":1783908583956,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82160602"],"award-info":[{"award-number":["No.82160602"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangxi Provincial Health Commission Science and Technology Program Project","award":["No.202410029"],"award-info":[{"award-number":["No.202410029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04393-5","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:16:11Z","timestamp":1779239771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of PD-1\/PD-L1 inhibitors combined with albumin-bound paclitaxel and fluorouracil-based agents as second-line therapy in biliary tract cancers"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"4393_CR1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2022.11.005","volume":"78","author":"J Merters","year":"2023","unstructured":"Merters J, Lamarca A. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J Hepatol. 2023;78:652\u20137.","journal-title":"J Hepatol"},{"key":"4393_CR2","doi-asserted-by":"publisher","first-page":"103706","DOI":"10.1016\/j.esmoop.2024.103706","volume":"9","author":"L Kehmann","year":"2024","unstructured":"Kehmann L, J\u00f6rdens M, Loosen SH, Luedde T, Roderburg C, Leyh C. Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets. ESMO Open. 2024;9:103706.","journal-title":"ESMO Open"},{"key":"4393_CR3","doi-asserted-by":"crossref","unstructured":"Vu QT, Nishimura Y, Harada K, Ito H, Higashionna T, Maruo A, Harada K, Takeda T, Hamano H, Zamami Y et al. International trends in biliary tract cancer-related mortality, 2000\u20132022: An observational study of the World Health Organization Mortality Database. Hepatology. 2024.","DOI":"10.2139\/ssrn.4905380"},{"key":"4393_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"4393_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4393_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2025.03.019","volume":"83","author":"C Yoo","year":"2025","unstructured":"Yoo C, Ueno M, Kl\u00fcmpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, et al. Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. J Hepatol. 2025;83:692\u2013700.","journal-title":"J Hepatol"},{"key":"4393_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701.","journal-title":"Lancet Oncol"},{"key":"4393_CR8","doi-asserted-by":"publisher","first-page":"100881","DOI":"10.1016\/j.drup.2022.100881","volume":"65","author":"ER Smith","year":"2022","unstructured":"Smith ER, Wang JQ, Yang DH, Xu XX. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat. 2022;65:100881.","journal-title":"Drug Resist Updat"},{"key":"4393_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"4393_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO-24-01383","volume":"43","author":"RT Shroff","year":"2025","unstructured":"Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L, Matin K, Mahipal A, Kalyan A, Javle MM, et al. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025;43:536\u201344.","journal-title":"J Clin Oncol"},{"key":"4393_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/apt.17623","volume":"58","author":"Z Lei","year":"2023","unstructured":"Lei Z, Ma W, Si A, Zhang Y, Yang F, Yu Q, Tang H, Xiao Q, Zhou J, Wang K, et al. Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma. Aliment Pharmacol Ther. 2023;58:611\u201322.","journal-title":"Aliment Pharmacol Ther"},{"key":"4393_CR12","doi-asserted-by":"publisher","first-page":"108642","DOI":"10.1016\/j.pharmthera.2024.108642","volume":"258","author":"M Duan","year":"2024","unstructured":"Duan M, Leng S, Mao P. Cisplatin in the era of PARP inhibitors and immunotherapy. Pharmacol Ther. 2024;258:108642.","journal-title":"Pharmacol Ther"},{"key":"4393_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-023-01422-8","volume":"16","author":"S Chen","year":"2023","unstructured":"Chen S, Li J, Dong A, Liu Z, Zhu M, Jin M, Wei G, Wu S, Wang Y, Chen Y, Peng Z. Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study. J Hematol Oncol. 2023;16:26.","journal-title":"J Hematol Oncol"},{"key":"4393_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","volume":"41","author":"D Liu","year":"2022","unstructured":"Liu D, Heij LR, Czigany Z, Dahl E, Lang SA, Ulmer TF, Luedde T, Neumann UP, Bednarsch J. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin Cancer Res. 2022;41:127.","journal-title":"J Exp Clin Cancer Res"},{"key":"4393_CR15","doi-asserted-by":"crossref","unstructured":"Hammons JN, Warren EK, Wittling MC, Bennett FJ, Rangel-Rivera GO, Mack AF, Phillips MJ, Robinson BS, Krasinskas AM, Horvat NK et al. Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma. Hepatology 2025.","DOI":"10.1097\/HEP.0000000000001439"},{"key":"4393_CR16","doi-asserted-by":"publisher","unstructured":"Heij L, Hayat S, Reichel K, Maryam S, O\u2019Rourke CJ, Tan X, van den Braber M, Verhoeff J, Halder M, Peisker F et al. Multimodal single-cell profiling reveals crosstalk between macrophages and stromal cells in poor prognostic cholangiocarcinoma patients. NPJ Precis Oncol. 2026;10(1):105. https:\/\/doi.org\/10.1038\/s41698-026-01292-6.","DOI":"10.1038\/s41698-026-01292-6"},{"key":"4393_CR17","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.7150\/thno.45777","volume":"11","author":"S Cai","year":"2021","unstructured":"Cai S, Chen Z, Wang Y, Wang M, Wu J, Tong Y, Chen L, Lu C, Yang H. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy. Theranostics. 2021;11:1970\u201381.","journal-title":"Theranostics"},{"key":"4393_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-022-01253-z","volume":"15","author":"T Xia","year":"2022","unstructured":"Xia T, Li K, Niu N, Shao Y, Ding D, Thomas DL, Jing H, Fujiwara K, Hu H, Osipov A, et al. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J Hematol Oncol. 2022;15:37.","journal-title":"J Hematol Oncol"},{"key":"4393_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929\u201338.","journal-title":"Ann Oncol"},{"key":"4393_CR20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Kl\u00fcmpen HJ, Chan SL, Ozaka M, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"4393_CR21","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"4393_CR22","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1016\/j.apsb.2021.07.029","volume":"11","author":"M Wang","year":"2021","unstructured":"Wang M, Chen S, Wei Y, Wei X. DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer. Acta Pharm Sin B. 2021;11:3935\u201349.","journal-title":"Acta Pharm Sin B"},{"key":"4393_CR23","doi-asserted-by":"publisher","first-page":"1278573","DOI":"10.3389\/fimmu.2023.1278573","volume":"14","author":"J Zhu","year":"2023","unstructured":"Zhu J, Yu Y, Mei J, Chen S, Li J, Jiang S. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer. Front Immunol. 2023;14:1278573.","journal-title":"Front Immunol"},{"key":"4393_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17:251\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"4393_CR25","doi-asserted-by":"publisher","first-page":"19736","DOI":"10.1021\/acsami.1c03065","volume":"13","author":"M Hama","year":"2021","unstructured":"Hama M, Ishima Y, Chuang VTG, Ando H, Shimizu T, Ishida T. Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System. ACS Appl Mater Interfaces. 2021;13:19736\u201344.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4393_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen H, Mo H, Zhao N, Sun X, Liu B, Gao R, Xu B, Zhang Z, Liu Z, Ma F. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell. 2025;43:446\u2013e463447.","journal-title":"Cancer Cell"},{"key":"4393_CR27","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1111\/ajco.13599","volume":"18","author":"R Woodford","year":"2022","unstructured":"Woodford R, Brungs D, Leighton C, Grimison P, Sjoquist KM, Becker T, Robinson S, Gebski V, Wilson K, Chantrill L, Aghmesheh M. Combination chemotherapy with NAB(\u00ae) -paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study). Asia Pac J Clin Oncol. 2022;18:e220\u20136.","journal-title":"Asia Pac J Clin Oncol"},{"key":"4393_CR28","doi-asserted-by":"publisher","first-page":"e249840","DOI":"10.1001\/jamanetworkopen.2024.9840","volume":"7","author":"GT Moffat","year":"2024","unstructured":"Moffat GT, Hu ZI, Meric-Bernstam F, Kong EK, Pavlick D, Ross JS, Murugesan K, Kwong L, De Armas AD, Korkut A, et al. KRAS Allelic Variants in Biliary Tract Cancers. JAMA Netw Open. 2024;7:e249840.","journal-title":"JAMA Netw Open"},{"key":"4393_CR29","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1111\/febs.70102","volume":"292","author":"S Zhao","year":"2025","unstructured":"Zhao S, Sun D, Yu H, Wang M, Xu B, Wang Y, Hu F, Wang X, Zhang J, Wang Y, Chai J. Oxaliplatin accelerates immunogenic cell death by activating the cGAS\/STING\/TBK1\/IRF5 pathway in gastric cancer. Febs j. 2025;292:3814\u201328.","journal-title":"Febs j"},{"key":"4393_CR30","doi-asserted-by":"publisher","first-page":"117273","DOI":"10.1016\/j.ejmech.2025.117273","volume":"285","author":"K Li","year":"2025","unstructured":"Li K, Gui S, Wang N, Li X, Zhao C, Liu M, Zhang Z. Sequential pH\/GSH-responsive stealth nanoparticles for co-delivery of anti-PD-1 antibody and paclitaxel to enhance chemoimmunotherapy of lung cancer. Eur J Med Chem. 2025;285:117273.","journal-title":"Eur J Med Chem"},{"key":"4393_CR31","doi-asserted-by":"publisher","first-page":"21365","DOI":"10.1021\/acsnano.4c18904","volume":"19","author":"L Kuang","year":"2025","unstructured":"Kuang L, Han M, Wu X, Deng Z, Liu T, Yin Y, Tang Y, Dong Z, Hu X, Zhu S, et al. Starting the Engine and Releasing the Brakes of T-Cell Responses: A Biomimetic Dendritic Cell Nanoplatform for Improved Glioblastoma Immunotherapy. ACS Nano. 2025;19:21365\u201384.","journal-title":"ACS Nano"},{"key":"4393_CR32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1186\/s12885-025-14581-3","volume":"25","author":"X Yang","year":"2025","unstructured":"Yang X, Dai YH, Peng H, Zhang MS, Fu Q, Liu SF, Sun L, Zou YM, Xu HS, Qiu P, et al. Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial. BMC Cancer. 2025;25:1321.","journal-title":"BMC Cancer"},{"key":"4393_CR33","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/10717544.2022.2046892","volume":"29","author":"Y Chen","year":"2022","unstructured":"Chen Y, Han L, Qiu X, Wang M, Chen Z, Cai Y, Xin Y, Lv Y, Hu A, Chai D, et al. Reassembling of albumin-bound paclitaxel mitigates myelosuppression and improves its antitumoral efficacy via neutrophil-mediated targeting drug delivery. Drug Deliv. 2022;29:728\u201342.","journal-title":"Drug Deliv"},{"key":"4393_CR34","doi-asserted-by":"publisher","first-page":"120816","DOI":"10.1016\/j.ijpharm.2021.120816","volume":"605","author":"LM Pham","year":"2021","unstructured":"Pham LM, Poudel K, Ou W, Phung CD, Nguyen HT, Nguyen BL, Karmacharya P, Pandit M, Chang JH, Jeong JH, et al. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles. Int J Pharm. 2021;605:120816.","journal-title":"Int J Pharm"},{"key":"4393_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2326-6066.CIR-23-0486","volume":"12","author":"J Chen","year":"2024","unstructured":"Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin SM, Matsui A, Hernandez A, Pu Z, Halvorsen S, et al. Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy. Cancer Immunol Res. 2024;12:400\u201312.","journal-title":"Cancer Immunol Res"},{"key":"4393_CR36","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","volume":"58","author":"MR Benmebarek","year":"2025","unstructured":"Benmebarek MR, Oguz C, Seifert M, Ruf B, Myojin Y, Bauer KC, Huang P, Ma C, Villamor-Pay\u00e0 M, Rodriguez-Matos F, et al. Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity. 2025;58:926\u2013e945910.","journal-title":"Immunity"},{"key":"4393_CR37","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jconrel.2021.12.023","volume":"341","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yu J, Li D, Zhao L, Sun B, Wang J, Wang Z, Zhou S, Wang M, Yang Y, et al. Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy. J Control Release. 2022;341:812\u201327.","journal-title":"J Control Release"},{"key":"4393_CR38","doi-asserted-by":"publisher","first-page":"1175809","DOI":"10.3389\/fimmu.2023.1175809","volume":"14","author":"W Hao","year":"2023","unstructured":"Hao W, Zhang J, Wang Y, Fang B, Jin S, Yuan J, Cai W. Immune-related adverse events associated with nab-paclitaxel\/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis. Front Immunol. 2023;14:1175809.","journal-title":"Front Immunol"},{"key":"4393_CR39","doi-asserted-by":"publisher","first-page":"1051130","DOI":"10.3389\/fimmu.2022.1051130","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Tang H, Fan J, Wang R, Han Y, Su S, Gan Y, Peng F, Rao M, Zhang J, et al. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. Front Immunol. 2022;13:1051130.","journal-title":"Front Immunol"},{"key":"4393_CR40","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/ijc.35313","volume":"156","author":"X Xie","year":"2025","unstructured":"Xie X, Chen L, Kong X, Huo Y, Huang W, Huang J, Zhang L, Jiang H, Gao J. Comparative efficacy and safety of PD-1 versus PD-L1 inhibitors in breast cancer treatment: A systematic review and meta analysis. Int J Cancer. 2025;156:1936\u201349.","journal-title":"Int J Cancer"},{"key":"4393_CR41","doi-asserted-by":"publisher","first-page":"1563300","DOI":"10.3389\/fimmu.2025.1563300","volume":"16","author":"W Ren","year":"2025","unstructured":"Ren W, Zhang H, Li Y, Sun W, Peng H, Guo H, Hou T, Wang M, Hu Z, Wu T, Liu B. Efficacy and safety of PD-1\/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis. Front Immunol. 2025;16:1563300.","journal-title":"Front Immunol"},{"key":"4393_CR42","doi-asserted-by":"publisher","first-page":"102218","DOI":"10.1016\/j.ctrv.2021.102218","volume":"98","author":"B Glimelius","year":"2021","unstructured":"Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev. 2021;98:102218.","journal-title":"Cancer Treat Rev"},{"key":"4393_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2022.02.004","volume":"166","author":"JWG Derksen","year":"2022","unstructured":"Derksen JWG, Smit KC, May AM, Punt CJA. Systematic review and non-inferiority meta-analysis of randomised phase II\/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer. Eur J Cancer. 2022;166:73\u201386.","journal-title":"Eur J Cancer"},{"key":"4393_CR44","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"4393_CR45","doi-asserted-by":"publisher","first-page":"114046","DOI":"10.1016\/j.ejca.2024.114046","volume":"203","author":"D Zhang","year":"2024","unstructured":"Zhang D, Dorman K, Westphalen CB, Haas M, Ormanns S, Neumann J, Seidensticker M, Ricke J, De Toni EN, Klauschen F, et al. Unresectable biliary tract cancer: Current and future systemic therapy. Eur J Cancer. 2024;203:114046.","journal-title":"Eur J Cancer"},{"key":"4393_CR46","doi-asserted-by":"publisher","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","volume":"6","author":"K Mody","year":"2022","unstructured":"Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ, et al. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precis Oncol. 2022;6:e2100510.","journal-title":"JCO Precis Oncol"},{"key":"4393_CR47","doi-asserted-by":"publisher","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2023.0009","volume":"20","author":"W Yi","year":"2023","unstructured":"Yi W, Yan D, Wang D, Li Y. Smart drug delivery systems to overcome drug resistance in cancer immunotherapy. Cancer Biol Med. 2023;20:248\u201367.","journal-title":"Cancer Biol Med"},{"key":"4393_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40364-022-00428-7","volume":"10","author":"Q Sun","year":"2022","unstructured":"Sun Q, Wang L, Zhang C, Hong Z, Han Z. Cervical cancer heterogeneity: a constant battle against viruses and drugs. Biomark Res. 2022;10:85.","journal-title":"Biomark Res"},{"key":"4393_CR49","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1016\/j.apsb.2024.05.028","volume":"14","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Luo W, Zheng C, Wang H, Hu R, Deng H, Shen J. Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy. Acta Pharm Sin B. 2024;14:4087\u2013101.","journal-title":"Acta Pharm Sin B"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04393-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04393-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04393-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:01:32Z","timestamp":1783908092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04393-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4393"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04393-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University (Ethical Approval Number: (2025) Medical Research Ethics Review (252)) and was registered with the Chinese Clinical Trial Registry (Registration Number: ChiCTR2600116737). All study procedures adhered to the ethical principles outlined in the Declaration of Helsinki. As this is a retrospective study using anonymized data, the ethics committee waived the requirement for individual patient informed consent for this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}